Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
Kathleen A Fairman, Lindsay E Davis, David A Sclar Department of Pharmacy Practice, College of Pharmacy, Midwestern University-Glendale, Glendale, AZ, USA Background: Inconsistency of real-world medication use with labeled indications may affect cost and clinical value of pharmacotherapy. PCSK-9 inh...
Saved in:
Main Authors: | Fairman KA (Author), Davis LE (Author), Sclar DA (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023) -
COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
by: Mohsin Haseeb, et al.
Published: (2023) -
Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
by: Zinan ZHAO, et al.
Published: (2020) -
Unusual Responses to PCSK9 Inhibitors in a Real-world Clinical Cohort
by: Bruce A. Warden, et al.
Published: (2020) -
Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
by: Zhen Feng, et al.
Published: (2022)